Eventide Asset Management’s Edwards Lifesciences EW Stock Holding History

Eventide Asset Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$513K	Buy	5,626 +750	+15%	+$62.8K	0.01%	235
2026 Q1	$388K	Buy	4,876 +1,420	+41%	+$117K	0.01%	232
2025 Q4	$298K	Buy	3,456 +255	+8%	+$20.9K	﹤0.01%	257
2025 Q3	$247K	Hold	3,201	–	–	﹤0.01%	239
2025 Q2	$250K	Buy	+3,201	New	+$239K	﹤0.01%	235
2024 Q1	–	Sell	-6,709	Closed	-$512K	–	166
2023 Q4	$512K	Sell	6,709 -3,085	-31%	-$215K	0.01%	150
2023 Q3	$679K	Buy	9,794 +4,686	+92%	+$377K	0.01%	149
2023 Q2	$482K	Buy	5,108 +1,078	+27%	+$93.7K	0.01%	135
2023 Q1	$333K	Buy	4,030 +1,423	+55%	+$112K	0.01%	141
2022 Q4	$195K	Buy	+2,607	New	+$201K	﹤0.01%	137

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Eventide Asset Management's EW Position: Q2 2026 in Review

Eventide Asset Management increased its Edwards Lifesciences (EW) stake by 15% in Q2 2026, buying an estimated $62.8K and bringing the position to 5,626 shares worth $513K. The position accounts for 0.01% of the portfolio, ranked #235.

Eventide Asset Management first reported a position in EW in Q4 2022 and has held it in 10 quarters since. The position peaked at $679K in Q3 2023. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

Eventide Asset Management held 5,626 shares of Edwards Lifesciences worth $513K as of Q2 2026.
Eventide Asset Management bought 750 Edwards Lifesciences shares in Q2 2026, an estimated $62.8K.
Edwards Lifesciences made up 0.01% of Eventide Asset Management's portfolio in Q2 2026, its #235 holding.
Eventide Asset Management first reported a position in Edwards Lifesciences in Q4 2022 and has held it in 10 quarters since.
Eventide Asset Management's Edwards Lifesciences position peaked at $679K in Q3 2023.
1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.